[Pulmonary hypertension and right ventricular failure. Part XII. Nitrous oxide and phosphodiesterase inhibitors in the treatment of primary pulmonary arterial hypertension].

Abstract

In a series of articles the authors discuss literature data concerning epidemiology of pulmonary arterial hypertension (PAH), its modern classification; peculiarities of its pathogenesis and treatment in various diseases and conditions. The twelfth communication contains consideration of inhaled nitrous oxide and three available inhibitors of phosphodiesterase type 5 (sildenafil, tadalafil, and vardenafil). The place of nitrous oxide in diagnostics and short term treatment of PAH is discussed. Analysis of results of randomized controlled studies assessing efficacy and safety of sildenafil in patients with primary (idiopathic) PAH and PAH associated with connective tissue diseases and congenital heart diseases with systemic-to-pulmonary shunts is presented.

• Authors: T A Batyraliev, S A Makhmutkhodzhaev, E Ekinci, S A Pataraia, I V Pershukov, B A Sidorenko, D V Preobrazhenskiĭ
• Journal: Kardiologiia (Kardiologiia) Vol. 47 Issue 8 Pg. 76-86 ( 2007) ISSN: 0022-9040 [Print] Russia (Federation)
• PMID: 18260920 (Publication Type: Lecture)

Chemical References

• Phosphodiesterase 5 Inhibitors
• Phosphodiesterase Inhibitors
• Nitrous Oxide

Topics

• Heart Failure (etiology)
• Humans
• Hypertension, Pulmonary (complications, drug therapy)
• Nitrous Oxide (metabolism, pharmacology, therapeutic use)
• Phosphodiesterase 5 Inhibitors
• Phosphodiesterase Inhibitors (therapeutic use)
• Ventricular Dysfunction, Right (etiology)